目的 探討膠體果膠鉍顆粒聯合替普瑞酮治療慢性萎縮性胃炎的臨床療效。方法 選取2015年7月-2016年2月在延安市人民醫(yī)院接受治療的慢性萎縮性胃炎84例，按照治療方法差別分為對照組和治療組，每組各42例。對照組口服替普瑞酮膠囊，1粒/次，3次/d。治療組在對照組基礎上口服膠體果膠鉍顆粒，1袋/次，4次/d。兩組患者均連續(xù)治療4周。觀察兩組的臨床療效，同時比較兩組治療前后臨床癥狀積分、C反應蛋白（CRP）、白細胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）、氧化物歧化酶（SOD）、一氧化氮（NO）、丙二醛（MDA）、胃泌素-17（G-17）、胃蛋白酶原I（PGI）、胃蛋白酶原II（PGII）的變化情況。結果 治療后，對照組和治療組的總有效率分別為76.19%、92.86%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組胃刺痛評分、倦怠乏力評分、胃脘脹滿評分、食少納呆評分均顯著降低，同組治療前后差異有統(tǒng)計學意義（P<0.05）；且治療組治療后這些評分低于對照組，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組CRP、IL-6、TNF-α、MDA水平明顯低于同組治療前，兩組患者血清NO、SOD、G-17、PGI、PGII水平明顯高于同組治療前，同組治療前后差異有統(tǒng)計學意義（P<0.05）；治療組治療后這些觀察指標的改善程度優(yōu)于對照組，兩組比較差異有統(tǒng)計學意義（P<0.05）。結論 膠體果膠鉍顆粒聯合替普瑞酮治療慢性萎縮性胃炎效果顯著，可明顯改善患者的臨床癥狀，降低血清炎性因子水平，改善機體氧化應激狀態(tài)及G-17、PGI、PGII水平，具有一定的臨床推廣應用價值。

Objective To investigate the effect of Colloidal Bismuth Pectin Granules combined with teprenone in treatment of chronic atrophic gastritis. Methods Patients (84 cases) with chronic atrophic gastritis in Yan'an People's Hospital from July 2015 to February 2016 were divided into control and treatment groups based on different treatments, and each group had 42 cases. The patients in the control group were po administered with Teprenone Capsules, 1 grain/time, three times daily. The patients in the treatment group were po administered with Colloidal Bismuth Pectin Granules on the basis of the control group, 1 bag/time, four times daily. The patients in two groups were treated for 4 weeks. After treatment, the efficacy was evaluated, and the changes of clinical symptoms scores, CRP, IL-6, TNF-α, SOD, NO, MDA, G-17, PGI, and PGII in two groups before and after treatment were compared. Results After treatment, the efficacies in the control and treatment groups were 76.19% and 92.86%, respectively, and there were differences between two groups (P<0.05). After treatment, stomach stabbing pain scores, languid scores, diagnosis bilge full scores, eat less stay scores in two groups were significantly reduced, and the difference was statistically significant in the same group (P<0.05). And those scores in the treatment group were lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of CRP, IL-6, TNF-α, and MDA in the two groups were significantly reduced, and levels of NO, SOD, G-17, PGI, and PGII were significantly increased, and the difference was statistically significant in the same group (P<0.05). The improvement of those observational indexes in the treatment group was better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Colloidal Bismuth Pectin Granules combined with teprenone has clinical curative effect in treatment of chronic atrophic gastritis, and can obviously improve the clinical symptoms, and lower the levels of serum inflammatory factors, also can improve the oxidative stress state and levels of G-17, PGI, PGII, which has a certain clinical application value.